Ubs Group Ag Gemini Therapeutics, Inc. Transaction History

Ubs Group Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$1.31 - $2.01 $100,306 - $153,905	-76,570 Reduced 55.3%	61,900 $102,000
Q2 2022 Aug 10, 2022	BUY	$1.22 - $1.73 $168,933 - $239,553	138,470 New	138,470 $234,000
Q4 2021 Feb 14, 2022	SELL	$2.39 - $4.0 $3,114 - $5,212	-1,303 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.3 - $6.32 $2,907 - $5,567	881 Added 208.77%	1,303 $5,000
Q2 2021 Aug 13, 2021	SELL	$6.32 - $14.02 $3,804 - $8,440	-602 Reduced 58.79%	422 $3,000
Q1 2021 May 12, 2021	BUY	$11.32 - $18.0 $11,591 - $18,432	1,024 New	1,024 $14,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.